ClinicalTrials.gg
RecruitingNCT06573593Updated Aug 27, 2024

Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

An observational study in Alopecia Areata and Janus Kinase Inhibitors, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 2 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
2 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Alopecia Areata with a site in China — 9 open to participants now, 13 under way, 6 of them phase 3. Alopecia Areata · China.

Started
2024
with 2 others
Observational
2 of 24
1 open now
Primary completion
2026-12
later than 2 of 12 live
Registered
16th of 24
by date
Lead sponsor
2 of 24
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 24 studies in Alopecia Areata with a site in China, this one is one of 3 that started in 2024, is one of 2 observational ones, reaches primary completion later than 2 of the 12 other live ones, and was the 16th registered.

Alopecia Areata

222 studies on the registry are indexed under Alopecia Areata; 63 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

9 of the 24 studies in Alopecia Areata with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Alopecia Areata studies recruiting now, 17 (40%) set no upper age limit and 22 (51%) stop at 75 or younger; 20 take children under 18; 6 take healthy volunteers.

This study: 2 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Alopecia Areata with a site in China, or all of them as a file.
02

Study summary

The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib,abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.

03

Conditions studied

  • Alopecia Areata
  • Janus Kinase Inhibitors

Browse trials for

04

Who can participate

Ages eligible
2 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with alopecia areata treated with JAKi including tofacitinib, baricitinib, ritlecitinib,abrocitinib, upadacitinib and ifidancitinib for more than 3 months in Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with alopecia areata between 2 to 18 years old
  • Patients diagnosed with alopecia areata according to AA guideline
  • AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib,abrocitinib, upadacitinib and ifidancitinib for more than 3 months

Exclusion criteria

Exclusion Criteria:

  • Patients had previously received hair implants
  • Other alopecia
  • Other diseases may induce alopecia including psoriasis, lichen planus, et al.
  • Unable to estimate SALT score at baseline or at follow-up
  • Patients are participating in other clinical trials
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Tofacitinib treated group

    In the real-world settings, patients with AA treated with tofacitinib.

    Drug: Tofacitinib

  • Baritinib treated group

    In the real-world settings, patients with AA treated with baritinib.

    Drug: Baricitinib

  • Ruxolitinib treated group

    In the real-world settings, patients with AA treated with ruxolitinib

    Drug: Ruxolitinib

  • Upadacitinib treated group

    In the real-world settings, patients with AA treated with upadacitinib.

    Drug: Upadacitinib

  • Abrocitinib treated group

    In the real-world settings, patients with AA treated with abhicitinib.

    Drug: Abrocitinib

  • Ritlecitinib treated group

    In the real-world settings, patients with AA treated with ritlecitinib.

    Drug: Ritlecitinib

Interventions

  • In the real-world settings, patients with AA treated with tofacitinib.

  • In the real-world settings, patients with AA treated with Baricitinib.

  • In the real-world settings, patients with AA treated with Ruxolitinib.

  • In the real-world settings, patients with AA treated with Upadacitinib.

  • In the real-world settings, patients with AA treated with Abrocitinib.

  • DrugPF-06651600Studies of PF-06651600PF-06651600 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In the real-world settings, patients with AA treated with Ritlecitinib.

06

What researchers measure

Primary outcomes

  1. Mean SALT

    Reduction of Severity of Alopecia Tool (SALT) score compared with baseline

    Time frame: at week 24

  2. SALT50

    Percentage of patient with more than 50% improvement in SALT score

    Time frame: at week 24

  3. SALT75

    Percentage of patient with more than 70% improvement in SALT score

    Time frame: at week 24

Secondary outcomes

  1. Mean SALT

    Reduction of Severity of Alopecia Tool (SALT) score compared with baseline

    Time frame: at week 12, 36, 48, 56

  2. SALT50

    Percentage of patient with more than 75% improvement in SALT score

    Time frame: at week 12, 36, 48, 56

  3. SALT75

    Percentage of patient with more than 50% improvement in SALT score

    Time frame: at week 12, 36, 48, 56

  4. Safety profile

    Any adverse events including infection, hypohepatia, thrombus, gastrointestinal reaction and any other system events.

    Time frame: at week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2024
First posted
Aug 27, 2024
StartActual
Jul 29, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06573593
Responsible party
Sponsor
First posted
Aug 27, 2024
Start date
Jul 29, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 27, 2024

Study contacts

Ru Dai, MD
Contact
dairu@zju.edu.cn
15982215914
Xianjie Wu, Ph.D
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion